Quizartinib is a therapeutic drug for patients with specific acute myeloid leukemia (AML). This article aims to introduce in detail the use of Quizartinib, drug interactions and precautions for special populations, so as to help patients better understand and apply this drug.
How to use Quizartinib
Quizartinib is a prescription drug, and its use must strictly follow the doctor's instructions.
Indications and targets
Quizartinib is mainly used to treat relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia. It targets FLT3 and exerts its therapeutic effect by inhibiting the activity of this kinase.
Dosage and administration
Usually, adult patients need to take Quizartinib orally once a day. The initial dose is 26.5 mg for two weeks, and then the dose is increased to 53 mg once a day. The specific dose may vary depending on the patient's condition and needs to be adjusted by the doctor according to individual conditions. During medication, patients should regularly monitor blood routine and electrocardiogram indicators.
Precautions
When using Quizartinib, patients should pay attention to adverse reactions such as QT interval prolongation, bone marrow suppression and bleeding. QT interval prolongation may lead to arrhythmia. Electrocardiogram should be performed before starting medication and before increasing the dose, and regular monitoring should be performed. Bone marrow suppression and bleeding risk increase, regular blood routine examination is required, and the patient's condition should be fully observed. Patients with severe liver damage are advised to use this product with caution.
The correct use of Quizartinib is very important for efficacy and effectiveness. Patients should strictly follow the doctor's instructions, take the medicine on time and in the right amount, and pay close attention to adverse reactions.
Quizartinib drug interactions
The interaction between Quizartinib and other drugs may affect its efficacy and effectiveness.
Strong CYP3A inhibitors
Strong CYP3A inhibitors, such as itraconazole and ketoconazole, can significantly increase the blood concentration of Quizartinib and increase the risk of adverse reactions. Co-administration should be avoided as much as possible. If it cannot be avoided, the dose of Quizartinib should be appropriately reduced.
Strong CYP3A inducers
Strong CYP3A inducers, such as rifampicin and rifapentine, can reduce the blood concentration of Quizartinib and weaken the efficacy. Co-administration should also be avoided. If it cannot be avoided, the dose of Quizartinib should be appropriately increased.
Drugs that prolong the QT interval
The combination of Quizartinib with drugs known to prolong the QT interval may further increase the risk of QT prolongation. Such drugs should be avoided as much as possible, such as bisoprolol and ibutilide.
Understanding the drug interactions of Quizartinib will help avoid potential drug conflicts.
Use of Quizartinib in special populations
Quizartinib should be used with special caution in special populations.
Pregnant and lactating women
Quizartinib may cause harm to the fetus. Pregnant women and women who may become pregnant should use it when they believe that the benefits of treatment outweigh the risks. It is best for lactating women not to breastfeed, as Quizartinib may be transferred into breast milk and cause potential harm to the baby.
People of childbearing potential
Women and men of childbearing potential should take effective contraceptive measures during the use of Quizartinib to avoid potential harm to the fetus.
Children and the elderly
The effectiveness of Quizartinib in children under 12 years of age has not been determined and should be used with caution. For elderly patients aged 65 years and above, no clinically significant difference in effectiveness was observed compared with younger patients.
When using Quizartinib in special populations, the medication regimen needs to be adjusted according to individual conditions to help the effectiveness of the medication.
